Navigation Links
Delcath to Present at the William Blair Emerging Growth Stock Conference
Date:9/28/2010

NEW YORK, Sept. 28 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) announced today that management will present at the William Blair Emerging Growth Stock Conference on Tuesday, October 5, 2010 at 8:45 a.m. ET in New York, NY. Mr. David McDonald, Chief Financial Officer, will provide an overview of the Company's business strategy and recent corporate developments.

Attendance at this conference is by invitation only. Delcath will offer a live audio webcast of its presentation, which may be accessed on the Investor Relations section of the Company's website at www.delcath.com. An archived replay of the presentation will be available for 90 days, also at www.delcath.com.

About Delcath Systems

Delcath Systems, Inc. is a development stage, specialty pharmaceutical and medical device company focused on oncology. Delcath's proprietary system for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. The Company's initial focus is on the treatment of primary and metastatic liver cancers. Delcath recently concluded a Phase III metastatic melanoma study, and the Company is currently conducting a multi–arm Phase II trial to treat other liver cancers. The Company has not yet received FDA or any foreign regulatory approval for commercial sale of its system. For more information, please visit the Company's website at www.delcath.com.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward–looking statements made by the Company or on its behalf. This news release contains forward–looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to the acceptability of the Phase III clinical trial data by the FDA, our ability to successfully complete an FDA new drug application, acceptance of the new drug application by the FDA, approval by the FDA or other regulatory authorities of the current or future drug delivery system for the treatment of metastatic melanoma, our ability to successfully complete other clinical trials and secure regulatory approval of our current or future drug–delivery system for the treatment of other liver cancers and other organs, the potential of chemosaturation therapy via PHP as a treatment for patients with terminal metastatic disease in the liver, actions by the FDA or other regulatory agencies, our ability to successfully enter into distribution and strategic partnership agreements in foreign markets and the corresponding revenue associated with such foreign markets, and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward–looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward–looking statements to reflect events or circumstances after the date they are made.


'/>"/>
SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Delcath to Present at the JMP Securities Healthcare Conference
2. Delcath Systems Announces Completion of Common Stock Offering
3. Delcath to Present at the 30th Annual Canaccord Global Growth Conference
4. Delcath to Present at the 2010 Wedbush Securities Life Sciences Best Ideas Management Access Conference
5. Delcath Systems Announces Second Quarter Progress Report Conference Call
6. Delcath Reconfirms Presentation During American Society of Clinical Oncology 2010 Annual Meeting in Chicago
7. Delcaths Eamonn Hobbs to Ring NASDAQ Opening Bell
8. Delcath Systems Provides Update on Corporate Developments
9. Delcath Signs First Partner Agreement in Asia
10. Delcath Systems Begins Data Analysis of Phase III Trial
11. Delcath Systems, Inc. to Present at the 12th Annual Needham Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/13/2017)... 2017 On Thursday, January 12, ... and the S&P 500 edged lower at the closing ... session in bearish territories. Taking into consideration yesterday,s market ... morning: Myriad Genetics Inc. (NASDAQ: MYGN ), ... Holdings Inc. (NASDAQ: INCR ), and La ...
(Date:1/13/2017)...  Secretary of Health Karen Murphy today ... at Misericordia University and discussed the Wolf Administration,s efforts ... . "The opioid epidemic is the ... my professional career," Secretary Murphy said. "This area of ... by heroin and prescription opioid overdoses. Across the commonwealth ...
(Date:1/13/2017)... , Jan. 13, 2017 Concord Medical Services ... CCM ), a leading specialty hospital management solution ... and diagnostic imaging centers in China ... fund with Zhongrong International Trust Co., Ltd. ("ZRT"). ... to set up Zhongrong Taihe Healthcare Fund in October ...
Breaking Medicine Technology:
(Date:1/16/2017)... ... January 16, 2017 , ... Board-certified oculoplastic surgeon Dr. ... the official journal of The American Society for Aesthetic Plastic Surgery, in which ... is designed to correct drooping, retracted lower eyelids, which usually result from genetics, ...
(Date:1/16/2017)... ... ... NexTec Group has been selected as a member of the Bob Scott’s VAR ... field of midmarket financial software. , Members of the VAR Stars were selected based ... on revenue and those firms chosen represent a wide range of size and many ...
(Date:1/15/2017)... California (PRWEB) , ... January 15, 2017 , ... "On ... stylistic slideshow with complete customization and ease," said Christina Austin - CEO of Pixel ... controls so that users can edit the style and animation of their slideshows. Place ...
(Date:1/14/2017)... (PRWEB) , ... January 14, 2017 , ... ... the distinctions among their expanding line of activated charcoal products. With more and ... importance of categorizing their products according to how they cater to specific needs. ...
(Date:1/13/2017)... ... 13, 2017 , ... The 18th European Congress: Perspectives in Lung Cancer will ... This Congress is expertly designed to meet the educational needs of European oncology ... , Chaired by Dr. Giorgio V. Scagliotti, Professor of Oncology at the University of ...
Breaking Medicine News(10 mins):